To the Editor: We thank Shil et al for their interest and comments on our study, "Youngervs Older-Old Patients with Heart Failure with Preserved Ejection Fraction." 1, 2 Although we did not examine the effects of therapies in the present study, we agree that investigation of the effects of therapeutic agents, such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, and estrogen replacement therapy, on heart failure with preserved ejection fraction (HFpEF) is important. Recent meta-analyses of randomized controlled trials (RCTs) did not show significant benefits of renin-angiotensin system inhibitors (ACEIs or ARBs) on mortality of patients with HFpEF. 3, 4 To date, no agent has been found to reduce mortality among patients with HFpEF. 5 However, HFpEF is a highly heterogeneous condition, and our study demonstrated significant differences in the clinical characteristics between HFpEF patients aged 65 to 84 years and those aged 85 years and older. 2 The negative results of RCTs examining therapeutic agents for HFpEF may be owing to such heterogeneity, and thus, specific HFpEF phenotypes that would benefit from certain treatments could be identified based on the phenotypic diversity of HFpEF. 6 Further well-organized RCTs are warranted to provide vital evidence for treating patients with HFpEF.
Shil et al also raised an important point regarding the relationship between HFpEF and frailty in the older-old patients. 1 Although we did not directly measure frailty in the present study, we analyzed body mass index (BMI) and reported that HFpEF patients aged 85 years and older had significantly lower BMI than those aged 65 to 84 years (median [interquartile range] = 20.6 [18.3-23.2] vs 22.3 [19. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .0] kg/m 2 , respectively; P < .001). 2 Therefore, we presume that our results are consistent with the comment by Shil et al 1 that frailty increases with age. Importantly, inflammation contributes significantly to frailty, and the association between aging and systemic proinflammatory states has been suggested. 7, 8 In this regard, the pathogenesis of HFpEF implies a systemic proinflammatory state as the origin of microvascular endothelial cell inflammation and subsequent cardiac remodeling and dysfunction, 8, 9 suggesting an association between frailty and HFpEF among the older patients. Indeed, the effect of frailty on mortality is high among older patients with heart failure. 10 As suggested by Shil et al, 1 developing therapies for frailty is an important area of research, and systemic inflammation could be one of the therapeutic targets.
In conclusion, the ultimate question is whether agents with therapeutic effects on HFpEF among the older patients can be found. We agree with Shil et al 1 that further research is warranted to address this important aspect. 
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